GLDC Antibody (H-9): sc-376196

GLDC Antibody (H-9) is a mouse monoclonal IgG2b kappa light chain antibody that detects GLDC protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). GLDC (H-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. GLDC protein, also known as glycine dehydrogenase, is a crucial component of the glycine cleavage system, which is essential for the catabolism of glycine, a key amino acid involved in numerous metabolic processes. GLDC protein is located in the mitochondria and functions as a homodimer, utilizing pyridoxal phosphate as a cofactor to facilitate the transfer of the methylamine group from glycine to the associated protein T. Proper functioning of GLDC protein is vital, as mutations in the gene encoding GLDC can lead to nonketotic hyperglycinemia (NKH), a serious autosomal recessive disorder characterized by the accumulation of glycine in body fluids and severe neurological symptoms. Anti-GLDC antibody (H-9) effectively detects and quantifies GLDC across different species, making this antibody an invaluable tool for research into metabolic disorders and mitochondrial function.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GLDC Antibody (H-9) References:

1. Human glycine decarboxylase gene (GLDC) and its highly conserved processed pseudogene (psiGLDC): their structure and expression, and the identification of a large deletion in a family with nonketotic hyperglycinemia.  |  Takayanagi, M., et al. 2000. Hum Genet. 106: 298-305. PMID: 10798358
2. Novel mutations in the P-protein (glycine decarboxylase) gene in patients with glycine encephalopathy (non-ketotic hyperglycinemia).  |  Toone, JR., et al. 2002. Mol Genet Metab. 76: 243-9. PMID: 12126939
3. Heterozygous GLDC and GCSH gene mutations in transient neonatal hyperglycinemia.  |  Kure, S., et al. 2002. Ann Neurol. 52: 643-6. PMID: 12402263
4. Mild glycine encephalopathy (NKH) in a large kindred due to a silent exonic GLDC splice mutation.  |  Flusser, H., et al. 2005. Neurology. 64: 1426-30. PMID: 15851735
5. Genetic heterogeneity of the GLDC gene in 28 unrelated patients with glycine encephalopathy.  |  Conter, C., et al. 2006. J Inherit Metab Dis. 29: 135-42. PMID: 16601880
6. Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemia.  |  Kanno, J., et al. 2007. J Med Genet. 44: e69. PMID: 17361008
7. Direct correlation between ischemic injury and extracellular glycine concentration in mice with genetically altered activities of the glycine cleavage multienzyme system.  |  Oda, M., et al. 2007. Stroke. 38: 2157-64. PMID: 17510459
8. Delivery of a normal baby after preimplantation genetic diagnosis for non-ketotic hyperglycinaemia.  |  Hellani, A., et al. 2008. Reprod Biomed Online. 16: 893-7. PMID: 18549703
9. Non-ketotic hyperglycinemia with a novel GLDC mutation in a Taiwanese child.  |  Chang, CY., et al. 2008. Acta Paediatr Taiwan. 49: 35-7. PMID: 18581728
10. Novel GLDC Compound Heterozygous Variant Leading to Nonketotic Hyperglycinemia: Case Report and Literature Review.  |  Cao, Y., et al. 2021. Front Pediatr. 9: 725930. PMID: 34513771
11. AAV-mediated expression of mouse or human GLDC normalises metabolic biomarkers in a GLDC-deficient mouse model of Non-Ketotic Hyperglycinemia.  |  Leung, KY., et al. 2024. Mol Genet Metab. 142: 108496. PMID: 38761651
12. An increased copy number of glycine decarboxylase (GLDC) associated with psychosis reduces extracellular glycine and impairs NMDA receptor function.  |  Kambali, M., et al. 2025. Mol Psychiatry. 30: 927-942. PMID: 39210012

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-GLDC Antibody (H-9) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-GLDC Antibody (H-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

GLDC Antibody (H-9) Specifications

Alternate Product Name: GLDC

Product Clone Name: H-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 256-555

Epitope Target: GLDC

Epitope Species: human

Product Reactivity/Detection: GLDC

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for GLDC Antibody (H-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin